Loading…
Trevi Therapeutics, Inc. is projected to rise to $23.61 by 2027, a +32% move from its current price of $17.84. TRVI is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $17.34 | $17.86 | $18.39 | +0.09% |
| Jul 14 | $17.15 | $17.87 | $18.63 | +0.18% |
| Jul 15 | $17.01 | $17.89 | $18.82 | +0.27% |
| Jul 16 | $16.89 | $17.90 | $18.98 | +0.36% |
| Jul 17 | $16.79 | $17.92 | $19.13 | +0.45% |
| Jul 18 | $16.70 | $17.94 | $19.27 | +0.55% |
| Jul 19 | $16.62 | $17.95 | $19.40 | +0.64% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $16.62 | $17.95 | $19.40 | +0.64% |
| Week 2 | $16.20 | $18.07 | $20.16 | +1.28% |
| Week 3 | $15.90 | $18.18 | $20.79 | +1.92% |
| Week 4 | $15.68 | $18.30 | $21.36 | +2.57% |
| Week 5 | $15.49 | $18.42 | $21.89 | +3.23% |
| Week 6 | $15.33 | $18.53 | $22.40 | +3.88% |
| Week 7 | $15.20 | $18.65 | $22.89 | +4.54% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing investigational therapies for chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, including refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in a phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial and a phase 2a trial in patients with refractory chronic cough.
Trevi Therapeutics has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Trevi Therapeutics, Inc. trades under the symbol TRVI. It has a current price of $18.63 and a market capitalization of $2.65B, with a rank of 1769. The company sits in the Healthcare category.
The outlook conveyed by the supplied forecast is bullish over the longer horizon, with the 2026 average price at $18.63 and rising in subsequent years to multi-decade highs.
A major floor 40.5% below — a decisive break under it would weaken the trend.
The nearest floor, 25.3% below — buyers have tended to step in here.
The nearest ceiling, 9.3% above — a clean break opens room to run.
A major ceiling 29.3% above — clearing it would confirm fresh momentum.
Key TRVI support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TRVI market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $18.46 | Sell | $18.26 | Sell |
| MA 10 | $18.33 | Sell | $18.08 | Sell |
| MA 20 | $17.26 | Buy | $17.32 | Buy |
| MA 50 | $15.35 | Buy | $15.77 | Buy |
| MA 100 | $13.83 | Buy | $14.38 | Buy |
| MA 200 | $12.52 | Buy | $12.55 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 57.87 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 31.67 | Neutral |
| Williams %R (14) | -78.30 | Info |
| MACD (12,26,9) | -0.03 | Sell |
| ROC (12) | 2.65 | Buy |
| Bollinger %B (20,2) | 0.59 | Neutral |
| Stochastic %K (14) | 21.70 | Neutral |
| TRIX (15) | 1.00 | Buy |
| Awesome (5,34) | 2.59 | Buy |
| Ultimate (7,14,28) | 48.38 | Neutral |
| Momentum (10) | -0.16 | Sell |
| Aroon Osc (25) | 80.00 | Buy |
| Hull MA (9) | 18.58 | Sell |
| ADX (14) | 31.54 | Buy |
| ATR (14) | 0.48 | Info |
In the near term, the 30-day technical picture shows bullish momentum. The RSI over 14 days is 80, while the 50-day simple moving average stands at $14.76 and the 200-day simple moving average at $12.13. Support is noted at $13.24 and resistance at $18.63, with a 30-day price range from $15.82 to $21.94.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $9.99 | $17.84 | $25.79 | 0% | Neutral | |
| $18.67 | $23.61 | $31.65 | +32% | Bullish | |
| $21.47 | $27.98 | $39.01 | +57% | Bullish | |
| $24.00 | $32.06 | $46.10 | +80% | Bullish | |
| $29.42 | $40.19 | $59.28 | +125% | Bullish | |
| $37.29 | $51.97 | $78.41 | +191% | Bullish | |
| $42.30 | $60.08 | $92.48 | +237% | Bullish | |
| $49.33 | $71.32 | $111.79 | +300% | Bullish | |
| $50.18 | $73.77 | $117.58 | +314% | Bullish | |
| $50.87 | $76.00 | $123.03 | +326% | Bullish | |
| $86.45 | $139.01 | $240.08 | +679% | Bullish | |
| $204.44 | $373.46 | $708.60 | +19.9x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $9.99 | $17.84 | $21.32 | +0.00% |
| August 2026 | $15.45 | $18.27 | $22.21 | +2.43% |
| September 2026 | $16.27 | $19.38 | $23.84 | +6.04% |
| October 2026 | $16.64 | $19.96 | $24.80 | +3.00% |
| November 2026 | $16.50 | $19.90 | $24.93 | -0.31% |
| December 2026 | $16.86 | $20.43 | $25.79 | +2.68% |
Click any year to see its month-by-month TRVI forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, TRVI is projected to trade between $9.99 and $25.79, averaging $17.84 — a potential gain of 0% from today's $17.84. Price action looks broadly range-bound.
Trevi Therapeutics, Inc.'s 2027 outlook centres on $23.61, within a $18.67 to $31.65 range. That is up +32% on the projected 2026 average. That marks a +32% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, TRVI could reach as high as $39.01, with a base case around $27.98 and support toward $21.47 — roughly +57% from $17.84. Momentum favours further upside here.
Expect TRVI to range from $24.00 to $46.10 through 2029. The $32.06 average target implies a +80% move from current prices. That is up +15% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The TRVI price prediction for 2030 points to an average of $40.19 (low $29.42, high $59.28) — a potential gain of +125% on today's $17.84. Momentum favours further upside here.
In 2031, TRVI is projected to trade between $37.29 and $78.41, averaging $51.97 — a potential gain of +191% from today's $17.84. That is up +29% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Trevi Therapeutics, Inc.'s 2032 outlook centres on $60.08, within a $42.30 to $92.48 range. That is up +16% on the projected 2031 average. That marks a +237% change versus current levels. Momentum favours further upside here.
By 2033, TRVI could reach as high as $111.79, with a base case around $71.32 and support toward $49.33 — roughly +300% from $17.84. Buyers look set to stay in control over this stretch.
Expect TRVI to range from $50.18 to $117.58 through 2034. The $73.77 average target implies a +314% move from current prices. That is up +3% on the projected 2033 average. Momentum favours further upside here.
The TRVI price prediction for 2035 points to an average of $76.00 (low $50.87, high $123.03) — a potential gain of +326% on today's $17.84. Buyers look set to stay in control over this stretch.
In 2040, TRVI is projected to trade between $86.45 and $240.08, averaging $139.01 — a potential gain of +679% from today's $17.84. That is up +83% on the projected 2035 average. Momentum favours further upside here.
Trevi Therapeutics, Inc.'s 2050 outlook centres on $373.46, within a $204.44 to $708.60 range. That is up +169% on the projected 2040 average. That marks a +19.9x change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in TRVI today (≈ 56.053812 TRVI) could be worth
$20,934.09
+$19,934.09 (+1993%) by 2050 · US Dollar
Based on the average projected TRVI price of $373.46 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TRVIwould be worth at today's price.
$1,000 invested in TRVI on Jul 10, 2025 (≈ 156.006244 TRVI) would be worth
$2,783.15
+$1,783.15 (+178.3%) today · 2.78× · US Dollar
Based on a TRVI entry price of $6.41 vs. today's $17.84.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $17.93 | $994.98 | -0.5% |
| 1 month ago | $13.4 | $1,331.34 | +33.1% |
| 3 months ago | $13.19 | $1,352.54 | +35.3% |
| 6 months ago | $11.29 | $1,580.16 | +58.0% |
| 1 year ago | $6.41 | $2,783.15 | +178.3% |
| All time (5.0y) ago | $2.02 | $8,831.68 | +783.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TRVI forecast.
Our base-case forecast reaches $36.00 around 2030.
Implied market cap at $36.00: $5.11B
The multi-year forecast outlines a rising price path with clear growth in average prices and bullish sentiment across many years. The 2026 forecast shows an average price of $18.63 (min $9.99, max $26.77) with a 0% ROI and neutral sentiment. From 2027 onward, the average price increases to $24.36 (ROI 30.8%), $29.03 (55.8%), $34.23 (83.7%), and $42.17 (126.4%) by 2030, with continued gains through 2035 where the average reaches $79.53 (326.9%).
The horizon extends to 2040 with an average of $140.49 (654.1% ROI) and a max of $230.62, and to 2050 with an average of $368.45 (1877.7% ROI) and a max of $657.99. Overall, the forecast remains bullish for the long term, though these are estimates and not guarantees, and actual results may differ.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $42.17, with a min of $31.74 and a max of $60.24. The implied ROI is 126.4% and the sentiment is bullish.
The forecast indicates a bullish trajectory from 2027 onward, with average prices rising from $24.36 in 2027 to $368.45 by 2050 and ROIs up to 1877.7%. The 2026 outlook is neutral with an average of $18.63 and ROI of 0%.
Yes. The forecast max values include $106.90 in 2033 and $113.87 in 2034, with higher maxima later—$230.62 in 2040 and $657.99 in 2050—indicating $100 is within the forecast range.
RSI(14) is 80, indicating strong momentum. The SMA(50) is $14.76 and SMA(200) is $12.13. The price currently sits at $18.63, with support at $13.24 and resistance at $18.63, and a 30-day range from $15.82 to $21.94.
The current price is $18.63 and the market capitalization is $2.65B, with a market rank of 1769.
Trevi Therapeutics, Inc. Community Discussion
0Share your Trevi Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.